- 1 ORIGINAL RESEARCH
- 2 Zen et al.

# 3 A Multi-center Study of COVID-19 with Multivariate Prognostic

- 4 Analysis
- 6 Wen Zeng\*1

- 7 Xin Feng\*<sup>1</sup>,
- 8 Jie Huang\*<sup>2</sup>
- 9 Chuan Du\*3
- 10 Dongming Qu\*<sup>4</sup>
- 11 Xiang Zhang<sup>5</sup>
- 12 Jianquan Zhang<sup>1</sup>
- 13 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical
- 14 University, Nanning, Guangxi 530021, China
- <sup>2</sup> The Fourth People's Hospital of Nanning City, Nanning, Guangxi, 530021, China
- <sup>3</sup> Hubei No.3 People's Hospital of Jianghan University, Wuhan, Hubei,430000, China
- 17 Annxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, 541000, China
- 18 <sup>5</sup>Wuhan Huangpi District Hospital of Traditional Chinese Medicine, Wuhan, Hubei, 430000, China
- \* These authors contributed equally to this project and should be considered co-first authors.
- 20 Correspondence:
- 21 Jianquan Zhang, MD, PhD
- Department of Respiratory and Critical Care Medicine, 1 Guangxi 530021, China
- 23 E-mail: jqzhang2002@126.com
- 24 Tel.: +86 139 7812 3845
- 25 Fax: +86 0771 535 0031

26 **Abstract:** 27 Purpose: Coronavirus disease (COVID-19) pandemic is now a global health concern. 28 29 However, there is no detailed analysis of the factors related to patients' improvement. 30 **Patients and methods:** We compared the clinical characteristics, laboratory findings, CT 31 images, and treatment of COVID-19 patients from two different cities in China. One hundred 32 and sixty-nine patients were recruited from January 27 to March 17, 2020 at five hospitals in 33 Hubei and Guangxi. They were divided into four groups according to age and into two groups 34 according to presence of comorbidities. Multivariate statistical analyses were performed for 35 the prognosis of the disease. 36 **Results:** Fifty-two patients (30.8%) had comorbidities, and the percentage of critical 37 COVID-19was higher in the comorbidities group (11.6% vs.0.9%, p<0.05). Older patients had 38 higher proportion of severe or critical disease. The results showed that lymphocyte count was 39 significantly associated with the number of days from positive COVID-19 nucleic acid test to 40 negative test; number of days from onset of symptoms to confirmation of diagnosis was 41 significantly associated with the time it took for symptoms to improve; and number of days 42 from onset of symptoms to confirmation of diagnosis and disease severity were significantly 43 associated with chest computed tomography improvement. 44 Conclusions: Age, comorbidities, lymphocyte count, and SpO<sub>2</sub> may predict the risk of severity of COVID-19. Early isolation, early diagnosis, and early initiation of management can slow 45 down the progression and spread of COVID-19. 46 47 48 **Keywords:** COVID-19; Severity; Multiple lung lobe involvement, prognosis

- 49 **Key Points:** Age and comorbidities can predict the risk of severity of COVID-19,
- 50 Lymphocyte count and SpO<sub>2</sub> may predict the risk of severity of COVID-19. Early isolation,
- Early diagnosis can slow down the progression of COVID-19

# 1.Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), has spread throughout the world, posing a critical threat to global health. COVID-19 has been declared as a public health emergency by the World Health Organization, and 3,175,207 laboratory-confirmed infections had been reported globally by May 1, 2020.1 Several studies have described the clinical characteristics and epidemiology of COVID-19.2-6 The novel corona virus has caused clusters of severe respiratory illness, similar to severe acute respiratory syndrome coronavirus.2,5Previous studies have also summarized the early clinical, laboratory, and computed tomography (CT)findings of COVID-19 pneumonia.3,6A multi-center study of clinical features showed that multiple organ dysfunction and impaired immune function were the typical characteristics of severe and critical disease, and advanced age (≥75 years) was a risk factor for mortality.4However, there is no detailed analysis of the factors related to patients' improvement. In this study, we analyzed the clinical features, laboratory findings, CT images, outcomes, and therapies (including antiviral drugs, antibacterial drugs, and corticosteroids)in 169 COVID-19 cases from three cities (Nanning and Guilin in Guangxi Province, and Wuhan in Hubei Province). We also analyzed the factors related to patients' improvement.

## 2.Methods

71

72 2.1. Study design and participants 73 Patients who were ≥18 years old were recruited for this multi-center retrospective study from 74 five hospitals designated for the treatment of COVID-19 in China, namely Guangxi Medical 75 University First Affiliated Hospital and The Fourth People's Hospital of Nanning City, both in 76 Nanning; Nanxishan Hospital of Guangxi Zhuang Autonomous Region, in Guilin, Guangxi 77 Province; and Wuhan Huangpi District Hospital of Traditional Chinese Medicineand Hubei 78 No.3 People's Hospital of Jianghan University, bothin Wuhan, Hubei Province. The 79 recruitment period was from January 27 to March 17, 2020. All patients enrolled in this study 80 were diagnosed with COVID-19 according to the diagnostic criteria from the Chinese Clinical 81 Guidance for COVID-19 Pneumonia Diagnosis and Treatment(7th edition), which was 82 produced by the National Health Commission of China.7 The study was approved by the Research Ethics Commission of Guangxi Medical University First Affiliated Hospital 83 84 approval number: 2020(KY-E-06). We grouped the patients according to their ages into group A (18–44 years), group B (45–64 85 86 years), group C (64–74 years), and group D (>75 years). Analysis of prognosis of improvement 87 included three aspects: number of days from positive COVID-19 nucleic acid test to negative 88 test, number of days from onset of illness(the first day of presenting with COVID-19-related 89 symptoms, such as fever, cough, and diarrhea)to improvement in symptoms, and improvement

### 2.2. Definitions

90

91

92

on the second CT scan. The primary outcomes were improvement and death.

93 According to the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and

Treatment (7th edition), COVID-19 is classified by severity into mild, moderate, severe, and

95 critical types.7

94

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

2.3. Data collection

The medical records of the recruited COVID-19 patients were reviewed and general information, epidemiological data, and data on clinical presentation, laboratory tests, chest CT scan findings, treatment modalities, and outcome were collected. Clinical data collection was completed on March 17, 2020. Du Chuang and Huang Jie cross-checked the data. The local Center for Disease Control (CDC) laboratories made definitive diagnosis of COVID-19 by analyzing throat-swab specimens from the upper respiratory tract or feces. Real-time reverse transcription polymerase chain reaction (RT-PCR) was used to confirm COVID-192 and exclude other viral infections. All patients underwent chest CT scan. Two attending radiologists were invited to interpret all chest CT scans independently, and they were blinded to the clinical information of each patient. The following CT features were assessed: distribution of lesions (peripheral, along the bronchi, random, or diffuse), number of lobes involved (one, two or three, or four or five), shape of lesions (patchy or nodular), appearance (ground-glass opacity [GGO], consolidation, or GGO with consolidation), specific focal signs (vascular thickening, crazy paving pattern, and fibrosis), and extrapulmonary manifestations (mediastinal and hilar lymph node enlargement, pleural effusion, or pleural thickening). In case of discordance between the interpretations of the two radiologists, the opinion of a third deputy chief physician radiologist was sought to reach a final decision. Data on follow-up, prognosis,

and treatment were updated on April 24, 2020.

2.4. Statistical analyses

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

Continuous variables were expressed as medians with interquartile ranges (IQR), and categorical variables were reported as frequencies and percentages. Differences between groups were compared using the independent samples t-test or Mann-Whitney test. The single factor analysis of variance (ANOVA) or Kruskal-Wallis H test was used, as appropriate, to compare the difference among the four groups into which patients were divided based on severity of the disease. Least significant difference (LSD) or Dunn's test was used for post hoc comparisons. Categorical data were analyzed either with Pearson Chi-square test or with Fisher's exact test. Two-tailed tests were performed to determine statistical significance at the 5% level. Bonferroni correction was used for pairwise comparison. Univariable and multivariable analyses for factors associated with the time for nucleic acid test to turn negative and the time of improvement of symptoms were performed with multiple linear regression analyses. Univariable and multivariable analyses for factors that are associated with chest CT improvement were done with Kaplan-Meier method and Cox proportional hazards regression model. Univariable and multivariable analyses for risk factors for disease severity and the relationship between age and disease severity were performed with logistic regression analyses. All data analyses were carried out using IBM Statistical Package for the Social Sciences for Windows, version 25 (SPSS Inc., Chicago, Illinois), and graphs were created using GraphPad Prism 7.0 software (GraphPad Software Inc., San Diego, CA, USA). P value less than 0.05 was considered statistically significant.

## 3. Results

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

The median age of the patients was 52.8 years (IQR, 19-82). Male patients accounted for 46.7% of all patients. Based on severity, 12 patients (7.1%) had mild COVID-19,137(81.1%) patients had moderate type, 13(7.7%) patients had severe type, and 7(4.1%) patients had critical type. The median number of days from the onset of illness to admission was 11.6 days (IQR, 18–92). Fifty-two patients had comorbidities, including hypertension, cardiovascular disease, diabetes, malignancy, cerebrovascular disease, chronic obstructive pulmonary disease(chronic obstructive pulmonary disease), chronic nephropathy, immunosuppression, and others. The most common morbidity was hypertension(17.8%). Clinical symptoms included fever, cough, sputum production, dry cough, pharyngalgia, shortness of breath, hemoptysis, myalgia, digestive symptoms, hypodynamia, and others. Fever was the most common symptom (76.9%), followed by dry cough (68%). Among the 169 patients, the lymphocyte count was decreased in 111 (65.68%) patients (median=1.24 (IQR=0.18-4.11) ×109/L). C-reactive protein (CRP) increased in 102 (65.39%) patients, lactate dehydrogenase (LDH) increased in 52 (33.33%) patients, and D-dimer increased in 55 (35.95%) patients. Alanine transaminase or aspartate aminotransferase was elevated in 56 patients (33.17%). Serum creatinine was elevated in 5 patients (2.96%), 4 patients had chronic nephropathy, and 1 patient's renal function returned to normal after treatment. One hundred and fifty-four (90.1%) patients received antiviral therapy within the first 3 days. Antivirals used included lopinavir, tonavir, abidor, ribavirin, ganciclovir, and oseltamivir. Most patients (53.9%) received antibacterial therapy, including moxifloxacin, cephalosporins, and azithromycin. Forty-eight (28.4%) patients received corticosteroids. One hundred and sixty-five (97.60%) patients improved, while four patients died.

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Among the 169 patients, 121 were from hospitals in Wuhan, while 48 were from hospitals in Guangxi. We compared the clinical data between the two groups. The Guangxi group had fewer days from onset of illness to admission (5.24:14.09) (p<0.05). Cough and sputum production were more common in the Wuhan group(p<0.05). The total protein and albumin in patients from Wuhan group were lower, while LDH was higher (p<0.05). The four patients who died were all in Wuhan group (Table 1). Among the 4 age groups into which patients were stratified, groups C and D had higher proportions of severe and critical disease than the other 2 groups, and group C had the highest proportion of severe disease among the 4 groups. Group A had the least proportion of patients with dyspnea, while group C had the highest. In both group C and group D, oxygen saturation(SpO2)was lower than 94%, and group C had the lowest SpO2. The lymphocyte count was lower in groups C and D than in groups A and B. LDH in group A was the lowest. CRP, pro-calcitonin (PCT), and interleukin (IL)-6 were significantly higher in groups C and D than in groups A and B. (Table 2). Fifty-two patients (30.8%) in the study had comorbidities. Compared with patients who had no comorbidities, the percentage of critical COVID-19 was higher in the comorbidities group(11.6%vs.0.9%; p<0.05). Patients with comorbidities were also more likely to have dyspnea(36.5% vs. 16.2%; p<0.05). The total protein and albumin values and lymphocyte counts in patients with comorbidities were lower, while increase in CRP and LDH was more obvious in this group. All4 patients who died had comorbidities (Table 3). To determine the association of disease severity with age, we divided all patients into 5 groups at intervals of 15 years, and analyzed the frequencies of severe and critical disease. We found

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

that older patients had higher proportion of severe or critical disease (Table 4). The 169 patients were also divided into two groups—mild group(including mild type and moderate type COVID-19,n=148) and severe group(including severe and critical type COVID-19, n=21)—and we then analyzed the risk factors for disease severity. The results showed that lymphocyte count and SpO2 at admission were factors that determined the risk factor of disease severity (Table5). A total of 116 patients with CT image data were enrolled in this study. The average time from onset of illness to CT imaging was  $10.73\pm7.97$  (0–34) days. The first CT imaging findings of the 116 patients were analyzed, and we found that 84(72.41%) patients had bilateral lung involvement,88(75.86%) patients hadperipheral lesions, and99(85.3%) patients had involvement of two or more lung lobes. The most common CT features were consolidation (66.4%), GGO (55.2%), linear opacity (55.20%), and mixed GGO and consolidation (33.60%). Forty (34.48%) patients had vascular thickening. We further divided the patients into 6 groups according to the number of days from onset of illness to repeat chest CT imaging: group1(≤7days, n=59), group2(8–14days, n=92), group3(15-21days, n=109), group4(22-28days, n=60), group5(29-45days, n=52), and group6(46-60days, n=18). Among the groups, group 1 had the highest percentage of GGO (48cases, 81.4%), and the least percentage of linear opacity (20cases, 33.9%). Group 2 had the highest percentage of consolidation (72cases, 78.3%). The proportion of cases with linear opacity gradually increased from group1 to group6, reaching 98.1% in group6. There were 4cases of reticular changes in group 1, and the proportion gradually increased to group 6, in which there were 7cases(Table 6).

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

To monitor the changes in CT images during the course of the disease, we considered the dynamic changes in the CT images of two patients from Guangxi, from onset to improvement of the disease: one with severe disease (patient1, Figure1) and the other with moderate disease (patient 2, Figure 2). As shown in Figure 1, patient 1 had ground glass opacity on chest CT in the early stage of the disease, and consolidation was noted on chest CT done on day 13 from onset of illness, as the patient's clinical symptoms improved. Consolidation had resolved on day 18 from onset of illness. Finally, the patient had linear opacity on day 23 from onset of illness. There were fifty-one patients when their clinical symptoms improved and they had checked chest CT (no more than 1 day before and after). Among them, the first CT findings were mainly GGO in 36 cases. When their clinical symptoms improved, 16 cases (44.4%) showed resolution of ground glass opacities but increased consolidation on repeat CT imaging, while 16 cases (44.4%) showed both GGO and resolution of consolidation. All 169 patients had positive real-time RT-PCR for COVID-19 nucleic acid on nasopharyngeal swab specimens. Twenty-five patients underwent nucleic acid test on stool samples: seven of them were positive, and six among them had diarrhea. Twenty patients underwent nucleic acid test of urine samples: one was positive, but he did not have symptoms of urinary tract infection. Vaginal secretions and semen tests were performed in 6 patients, all of which were negative. We designed three prognostic models: model 1 was based on number of days from positive COVID-19 nucleic acid test to negative test, model 2 was based on number of days from onset of illness to improvement in symptoms, and model 3 was based on whether the second CT scan was better than the first. There were 79 cases included in model 1, and multivariable analysis showed that lymphocyte count was significantly associated with the number of independent risk factor of days for positiveCOVID-19 nucleic acid test to become negative(Table 7, Figure 3). There were 53 cases included in model 2, and multivariable analysis showed that number of days from onset of illness to confirmation of diagnosis was significantly associated with an independent risk factor of the time it took for symptoms to improve (Table 8, Figure 4). The average number of days from the first CT scan to the second CT scan was 5.35 days, and we took 6 days as the time point for evaluating whether the CT scans improved or not. A total of 62 patients were included in model 3, and multivariable analysis showed that number of days from onset of illness to confirmation of diagnosis and disease severity were significantly associated with independent risk factors of chest CT improvement (Table 9).

#### 4. Discussion

This study summarizes the clinical characteristics, laboratory findings, dynamic changes in CT images, treatment, and prognosis of 169 COVID-19 patients from 5 hospitals in a western China city and in the city of disease onset, Wuhan. The study included mostly mild cases of COVID-19, which accounted for 88.2%. We analyzed the disease progression in three ways: number of days from positive COVID-19 nucleic acid test to negative test, number of days from onset of illness to improvement in symptoms, and improvement in second CT scan compared to the first. At present, no similar large sample data has been reported.

The study showed that the common symptoms of COVID-19 were fever, cough, sputum production, dyspnea, diarrhea, and myalgia. The main abnormalities in laboratory tests included that lymphocytopenia and increase in levels of CRP, LDH, and D-dimer, while PCT was normal. These findings are consistent with other literature reports.4,5,8,9 The most common comorbidities were hypertension, cardiovascular disease, and diabetes. Chronic

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

obstructive pulmonary disease was rare. Both clinical symptoms and laboratory tests indicated that patients with comorbidities had worse course of the disease, with higher proportion of severe or critical disease and poorer prognosis. Patients with comorbidities manifested with more dyspnea, lower lymphocyte count, and higher LDH, compared with those who had no comorbidities. These were manifestations of COVID-19 disease, rather than worsening symptoms of the comorbidities due to infection with SARS-Cov-2. We also found that the proportion of critical type COVID-19 increased with age. Lower lymphocyte count and SpO2were found in a higher proportion of patients with severe or critical type. These findings suggest that healthcare providers should pay particular attention to age, comorbidities, lymphocyte count, and SpO2 in the diagnosis and treatment of COVID-19. These factors may predict the progression of the patient from moderate to severe or critical type. Early CT findings showed that the lung lesions were mainly bilateral, mainly involved two or more lobes, and were mainly distributed in the peripheral zones of the lung. GGO, consolidation and mixed GGO and consolidation were the most common CT findings, while pleural effusion was rare. This is also consistent with previous literature reports.10 Through statistical analysis of lung CT imaging on different days in the course of the disease, we found the following progression: the early CT finding was GGO (1–7 days); the GGO lesion resolved or gradually evolved into consolidation shadow (1–2 weeks); consolidation resolved (2–3 weeks); then, linear opacity or reticular changes developed (4–6 weeks). The whole course took about a month. In the statistical analysis of the correlation between symptom improvement and pulmonary imaging changes in 36 patients, nearly half of the patients (16/36) showed resolution of GGO lesions and aggravation of consolidation lesions when the clinical

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

symptoms improved. Histological Lung biopsy specimen showed interstitial mononuclear inflammatory infiltrates (dominated by lymphocytes), diffuse alveolar damage with cellular fibro-myxoid exudate, or hyaline membrane formation. 11 This is different from what is seen in bacterial pneumonia. Therefore, the change in extent of GGO lesions can be used to predict the outcome of the disease, while consolidation shadow should not be used as aprognostic factor for the patients' condition. In this study, all patients had positive nucleic acid tests for pharyngeal swabs. Seven cases had positive nucleic acid test for stool samples, but only six cases had diarrhea. One patient tested positive for urine nucleic acid test, which is a rare report at present, and may suggest that SARS-Cov-2 may cause urinary tract infection. Most of the patients in this study were treated with antiviral drugs, including lopinavir and tonavir. Currently, there are no research data that show that such drugs have a clear effect on COVID-19. In this study, we found that the lower the lymphocyte count, the more the number of days for nucleic acid test to change from positive to negative. The longer the duration from onset of illness to admission, the longer the duration before improvement of symptoms, and the shorter the duration from onset of illness to admission, the shorter the duration for CT image improvement. Comparing patients in Hubei and Guangxi, we found that patients from Hubei had more severe disease and more days from onset of illness to admission than those from Guangxi. All of these findings suggest that early isolation, early diagnosis, and early initiation of management can contribute to slowing down the progression and spread of COVID-19. The present study has some limitations. First, due to the limited number of cases, some results need to be further validated with more patients. Second, the effect of antiviral agents and corticosteroidson COVID-19 needs further validation. Prospective studies should be performed to get more accurate results. Third, because this was a retrospective analysis, the time of CT imaging and nucleic acid test was not standardized and unified, t may have reduced the accuracy of the result. More cases need to be analyzed to obtain more information.

# 5. Conclusions

In this study, we found that older patients and patients with comorbiditieshad higher proportion of severe or critical type COVID-19. Lymphocyte count and SpO2 at admission were associated with disease severity. Early isolation, early diagnosis, and early initiation of management can contribute to slowing down the progression and spread of COVID-19. These findings will be helpful for the diagnosis and treatment of COVID-19.

# Funding

This research received no external funding.

#### **Disclosure**

The authors declare no conflicts of interest associated with this manuscript.

## **Author Contributions**

WZ made substantial contributions to the conception and design of the study; acquisition, analysis, and interpretation of the data; and drafting of the manuscript. XF, JH, CD and DQ made substantial contributions to the conception and design of the study; acquisition, analysis, and interpretation of the data; and critical revision of the manuscript for important intellectual content. XZ and JZ also gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

accuracy and integrity of any part of the work are appropriately investigated and resolved. JZ gave final approval of the version to be published. WZ and XF participated in analysis and interpretation of the data and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. WZ and JZ conceived of the study, participated in its design, and helped to draft the manuscript. All authors read and approved the final manuscript. Acknowledgements We would like to thank the three radiologists, Drs. Yanyan Shen, Peng Peng, Dong Deng, who helped with the analysis and interpretation of the imaging data. Ethical approval This study was approved by the ethics committee associated with the Faculty of Medicine at The First Affiliated Hospital of Guangxi Medical University[2020(KY-E-06).]. Informed consent was done appropriately for subjects. **References** 1.World Health Situation Report-102. Available Organization. at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200501-covid-19-sitrep.pdf?sfvrsn=7 42f4a18\_4.AccessedMay 1, 2020. 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:496. doi: 10.1016/S0140-6736(20)30252-X. 3.Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. Am J Roentgenol2020;1-6.doi: 10.2214/AJR.20.22961. 4.Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J

334 Respir Crit Care Med 2020;201:1380-8. 335 5.Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel 336 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.doi: 337 10.1016/S0140-6736(20)30211-7. 338 6.Rong W, Lingli X, Peng D, Fan H, Song M. Clinical characteristics of 96 hospitalized patients with 339 coronavirus disease 2019. Chin J Respir Crit Care Med 2020;19:144-7. 340 7. China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and 341 Treatment (7th edition). Available at: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html. Accessed on 342 April 1, 2020. 343 8.Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for 344 fighting the storm. Eur J Clin Invest2020;50:e13209.doi: 10.1111/eci.13209. 345 9. Holshue ML, Debolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J 346 Med2020;382:929-36.doi: 10.1056/NEJMoa2001191. 347 10.Li B, Li X, Wang Y, et al. Diagnostic value and key features of computed tomography in coronavirus disease 348 2019.Emerg Microbes Infect2020; 9:787-93.doi: 10.1080/22221751.2020.1750307. 349 11.Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress 350 syndrome. Lancet Respir Med2020;8:420-2.doi: 10.1016/S2213-2600(20)30076-X. 351 352 353 354 355

Table1: Clinical features of study subjectsin different locations

Characteristics	All (n=169)	Locations	p value	
		Wuhan(n=121)	Guangxi(n=48)	
Median age (IQR) - yrs	52.8 ( 18–92 )	53.9 ( 25–92 )	47.9 ( 18–85 )	0.027
Sex - no./total no.(%)				0.881
Male	79/169 ( 46.7 )	57/121 ( 47.1 )	22/48 ( 45.8 )	-
Female	90/169 ( 53.3 )	64/121 ( 52.9 )	26/48 ( 54.2 )	-
Disease Severity- no./total no.(%)				0.073
Mild	12/169 ( 7.1 )	5/121 ( 4.1 )	7/48 ( 14.6 )	-
Moderate	137/169( 81.1 )	103/121 ( 85.1 )	34/48 ( 70.8 )	-
Severe	13/169 ( 7.7 )	8/121 ( 6.6 )	5/48 ( 10.4 )	-
Critical	7/169 ( 4.1 )	5/121 ( 4.1 )	2/48 ( 4.2 )	-
Days from onset of illness to admission - median days (IQR) Symptoms - no./total	11.66 ( 0–45 )	14.09 ( 0–45 )	5.24 ( 1–20 )	<0.001
no.(%)				
Fever	130/169( 76.9 )	96/121 ( 79.3 )	34/48 ( 70.8 )	0.237
Dry cough	115/169 ( 68 )	88/121 ( 72.7 )	27/48 ( 56.3 )	0.038

Sputum production	46/169 ( 27.4 )	45/121 ( 37.5 )	1/48 ( 2.1 )	<0.001
Shortness of breath	38/169 ( 22.5 )	31/121 ( 25.6 )	7/48 ( 14.6 )	0.121
Myalgia	15/169 ( 8.9 )	14/121 ( 11.6 )	1/48 ( 2.1 )	0.070
Digestive symptoms	29/169 ( 17.3 )	22/121 ( 18.3 )	7/48 ( 14.6 )	0.576
Comorbidities-				
no./total no. (%) Any comorbidity	52/169 ( 30.8 )	40/121 ( 33.1 )	12/48 ( 25.0 )	0.306
Hypertension	30/169 ( 17.8 )	23/121 ( 19.0 )	7/48 ( 14.6 )	0.497
Cardiovascular disease	14/169 ( 8.3 )	11/121 ( 9.1 )	3/48 ( 6.3 )	0.759
Diabetes	11/169 ( 6.5 )	10/121 ( 8.3 )	1/48 ( 2.1 )	0.183
Malignancy	1/169 ( 0.6 )	1/121 ( 0.8 )	0/48 ( 0 )	1.000
Cerebrovascular disease	5/169 ( 3.0 )	5/121 ( 4.1 )	0/48 ( 0 )	0.323
COPD or chronic bronchitis	4/169 ( 2.4 )	4/121 ( 3.3 )	0/48 ( 0 )	0.579
Others	10/169 ( 5.9 )	9/121 ( 7.4 )	1/48 ( 2.1 )	0.285
Laboratory findings- median (IQR)				
SpO <sub>2</sub> -%	95.73			
	( 70–100 )	95.72 ( 70–100 )	96 ( 87–100 )	0.364
Total protein - g/L	68.69			
	( 36.7–98.0 )	66.68 ( 36.7–98.0 )	73.62 ( 54.7–86.3 )	<0.001
Albumin - g/L	38.8( 18–53.8 )	37.78 ( 18–53.8 )	41.19 ( 24.6–53.0 )	0.004
Globulin - g/L	29.86	20.07 ( 0.0 47.2 )	22 20 / 22 0 7/7	0.002
	( 9.8–54.5 )	28.87 ( 9.8–47.2 )	32.38 ( 23.0–54.5 )	0.002
Total bilirubin -	12.72	14 12 / 50 40 2 \	000/27/20\	ρ Δ1 1
μmol/L	( 2.7–62.0 )	14.13 ( 5.8–49.2 )	7.00 ( 4./-04.U )	0.011
ALT-U/L	44.62	49.98 ( 2.0–547.7 )	30.46 ( 18.0–65.2 )	0.006

	( 2.0–574.7 )			
AST-U/L	42.83			
	(5.0–584.0)	47.79 ( 9.0–584 )	29.74 ( 5.0–72.8 )	0.007
GGT-U/L	78.24 ( 7–906 )	74.69 ( 7–906 )	130.3 ( 9–601 )	0.585
Creatinine - µmol/L	73.4			
	( 34.5–359 )	75.88 ( 39–359 )	68.2 ( 34.5–245 )	0.276
White blood cell count $-\times 10^9/L$	7.07( 1.01–65 )	7.18 ( 1.01–65 )	6.77 ( 2.3–19.4 )	0.731
Neutrophilcount -	5.12			
×10 <sup>9</sup> /L	( 0.52–55.6 )	5.17 ( 0.52–55.6 )	5 ( 0.8–17.6 )	0.862
lymphocyte cell count	1.24			
- ×10 <sup>9</sup> /L	( 0.18–4.11 )	1.26 ( 0.18–4.11 )	1.18 ( 0.20–2.40 )	0.454
Hemoglobin - g/L	130.51			
	(84–230)	130.39 ( 84–230 )	131.13 ( 96–219 )	0.873
Platelet count - $\times 10^9/L$	222.35			
	( 55–564 )	219.12 ( 55–538 )	238.78 ( 119–564 )	0.328
C-reactive protein -	33.77	31.19		
mg/L	( 0.04–285 )	( 0.04–254.35 )	40.05 ( 0.5–285 )	0.316
PCT - μg/mL	0.35			
	( 0.02-6.02 )	0.37 ( 0.02–6.02 )	0.29 ( 0.02–2.94 )	0.468
LDH - U/L	263.16			
	( 120–808 )	281.56 ( 120–808 )	227.65 ( 151–610 )	0.009
Creatine kinase - U/L	107.53			
	( 12–1381 )	110.94 ( 28–1381 )	101.81 ( 12–355 )	0.745
CK-MB - U/L	13.91 ( 1–73 )	13.02 ( 4–45.7 )	15.12 ( 1–73 )	0.305
PT-s	14.65			
	( 9.7–100 )	15.43 ( 9.7–100 )	13.09 ( 10.5–17 )	0.081
D-dimer - μg/ml	2.16 ( 0–89 )	2.7 ( 0–89 )	0.76 ( 0.02–20.58 )	0.292
Treatment- no./total				

no. (%)				
Antiviral	91/169( 53.85 )	73 ( 60.30 )	18 ( 37.50 )	0.007
Antibiotics	154/169			
		108 ( 89.30 )	46 ( 95.80 )	0.291
	( 91.10 )	,	( , , , , ,	
Corticosteroids				
Corticosterolus	48/169( 28.40 )	42 ( 34.70 )	6 ( 12.50 )	0.004
Outcome- no./total no.				0.561
(%)				0.001
Improvement	165/169			
improvement	100/109	117/121 ( 96.70 )	48/48 ( 100 )	
	( 97.60 )	117/121 ( 90.70 )	40/40 ( 100 )	
<b>D</b> 41				
Death	4/169 ( 2.40 )	4/121 ( 3.30 )	0/48 ( 0 )	
	•	• •	` ,	

IQR=interquartile range, COPD=chronic obstructive pulmonary disease, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatine kinase-MB, PT=prothrombin time

Sputum production	10/52 ( 19.2 )	22/70 ( 31.9 )	11/35 ( 31.4 )	3/12 ( 25 )	0.43
Shortness of breath	3/52 ( 5.8 )	14/70 ( 20.0 ) $^{\mathrm{AB}}$	17/35 ( 48.6 ) <sup>AC</sup>	4/12 ( 33.3 ) <sup>AD</sup>	<0.001
Myalgia	2/52 ( 3.8 )	8/70 ( 22.4 )	4/35 ( 11.4 )	1/12 ( 8.3 )	0.395
Digestive symptoms	9/52 ( 17.3 )	11/70 ( 15.7 )	7/35 ( 20 )	2/12 ( 16.7 )	0.944
Comorbidities - no./total no.(%)					
Any comorbidity	6/52 ( 11.5 )	21/70 ( 30 )	19/35 ( 54.3 )	6/12 ( 50.0 )	<0.001
Hypertension	3/52 ( 5.8 )	10/70 ( 14.3 )	12/35 ( 34.3 )	5/12 ( 41.7 )	0.001
Cardiovascular disease	2/52 ( 3.8 )	7/70 ( 10.0 )	5/35 ( 14.3 )	0/12 ( 0 )	0.257
Diabetes	0/52 ( 0 )	2/70 ( 2.9 )	8/35 ( 22.9 )	1/12 ( 8.3 )	<0.001
Malignancy	0/52 ( 0 )	0/70 ( 0 )	1/35 ( 2.9 )	0/12 ( 0 )	0.278
Cerebrovascular disease	0/52 ( 0 )	0/70 ( 0 )	1/35 ( 2.9 )	4/12 ( 33.3 )	<0.001
COPD	0/52 ( 0 )	0/70 ( 0 )	3/35 ( 8.5 )	1/12 ( 8.3 )	0.006
Others	2/52 ( 3.8 )	5/70 ( 7.1 )	2/35 ( 5.7 )	1/12 ( 8.3 )	0.825
Laboratory findings- median (IQR)					

SpO <sub>2</sub> -%	97.31 ( 93–100 )	96.17 ( 70–99 )	93.26 ( 76–98 )	93.55 ( 80–98 )	0.032
Total protein - g/L	73 ( 57–86.3 )	68.5 ( 36.7–98 ) <sup>AB</sup>	63.5 ( 53.4–82.2 ) <sup>AC,BC</sup>	65.7 ( 51–81.8 ) <sup>AD</sup>	<0.001
Albumin - g/L	43.3 ( 32.6–53 )	38.6 ( 18–53.8 )	33.3 ( 20–44.5 )	36.1 ( 27–44 )	<0.001
Globulin - g/L	29.7 ( 22–39.7 )	29.9 ( 9.8–47.2 )	30 ( 19–54.5 )	29.5 ( 18–41.8 )	0.947
Total bilirubin - μmol/L	11.9 ( 2.91–49.2 )	11.5 ( 2.8–33 )	12.8 ( 2.7–48 )	20.5 ( 5.9–62 )	0.151
ALT-U/L	45 (7–547.7)	50.4 ( 11–479 )	32.3 ( 10–81 )	41.5 ( 2–101 )	0.626
AST-U/L	35.1 ( 9–352.7 )	49.2 ( 13–584 )	38.1 ( 5–157 )	51.6 ( 20–109.2 )	0.540
GGT-U/L	93.5 ( 10–906 )	82.2 ( 8–527 )	72.8 ( 7–601)	44 ( 7–906 )	0.766
Creatinine - μmol/L	61 ( 34.5–91 )	74.2 ( 41–241 )	78 ( 46.1–245 )	104.5 ( 60–359 )	0.001
White blood cell count - ×10 <sup>9</sup> /L	6.78 ( 2.3–60.9 )	7.46 ( 2.34–65 )	7.1 ( 1.01–19.4 )	5.9 ( 1.92–13.61 )	0.893
Neutrophil count - ×10 <sup>9</sup> /L	4.76 ( 0.8–55.6 )	5.2 ( 1.12–20.71 )	5.62 ( 0.52–17.6 )	5.1 ( 1.03–10.66 )	0.91
Lymphocyte count - $\times 10^9/L$	1.43(0.43–3.3)	1.31(0.23-4.11)	0.94(0.18-2.2) <sup>AC,BC</sup>	0.85(0.2-2.07) <sup>AD.BD</sup>	0.001
Hemoglobin - g/L	137.47 ( 102–230 )	131.48 ( 100–191 )	123.5 ( 84–177 )	114.72 ( 87–147 )	0.001
Platelet count - ×10 <sup>9</sup> /L	218.5 ( 55–431 )	225.73 ( 84–564 )	243 ( 100–538 )	167.36 ( 85–250 )	0.108

C-reactive protein - mg/L	17.76 ( 0.04–78.95 )	30.11 ( 0.4–149.68 )	46.84 ( 0.4–285 )	88.57 ( 1–254.35 )	0.006
PCT -μg/mL	0.21 ( 0.02–0.67 )	0.34 ( 0.04–2.57 )	0.49 ( 0.03-6.02 )	0.56 ( 0.08–2.05 )	0.017
LDH - U/L	212.86 ( 120–681 )	275.74 ( 123–686 ) <sup>AB</sup>	282.2 ( 175–544 ) <sup>AC</sup>	369.09 ( 177–808 ) <sup>AD</sup>	<0.001
Creatinekinase - U/L	117.42 ( 31.4–1381 )	101.87 ( 28–355 )	88.87 ( 12–216 )	120.6 ( 43–600 )	0.891
CK-MB - U/L	14.09 ( 5–68 )	12.75 ( 4–45.7 )	17.34 ( 6–73 )	16.52 ( 5–32.26 )	0.405
PT-s	0.24 ( 0.01–1.23 )	0.88 ( 0-7.8 )	4,23 ( 0.02–80 )	10.66 ( 0.18–89 ) <sup>AD,BD,CD</sup>	<0.001
D-dimer - μg/ml	13.16 ( 9.7–15.8 )	13.37 ( 9.7–29.3 )	15.57 ( 10.9–76 )	21.87 ( 12.6–100 ) <sup>AD.BD</sup>	0.001
Immunology – median (IQR)					
IgG- g/L	11.53 ( 7.84–15.16 )	13.39 ( 7.42–20.81 )	12.66 ( 7.96–16.69 )	12.75 ( 7.24–19.18 )	0.647
IgA- g/L	2.15 ( 1.32–3.44 )	2.63 (1.37-5.09)	2.07 ( 1.47–3.34 )	2.65 ( 2.38–4.71 )	0.26
IgM- g/L	1.42 ( 0.64–2.29 )	1.53 ( 0.64–3.15 )	1.37 ( 0.82–2.55 )	1.18 ( 0.38–2.49 )	0.662
IgE- g/L	74.77 ( 2.4–480.1 )	124.38 ( 1.3–1100 )	32.85 ( 0.8–76.1 )	154.15 ( 2.8–1008 )	0.717
IL-6- pg/mL	1.69 ( 15–2.84 )	6.76 ( 1.5–42.53 )	33.57 ( 1.5–223.81 )	71.34 ( 2.89–252.7 )	0.007
C3- g/L	0.94 ( 0.8–1.3 )	0.94 ( 0.6–1.3 )	0.85 ( 0.8–1 )	0.94 ( 0.6–1.4 )	0.701

C4- g/L	0.199 ( 0.1–0.4 )	0.18 ( 0.1–0.3 )	0.18 ( 0.1–0.2 )	0.22 ( 0.1–0.4 )	0.61
CD3+ cell count - cell/μl	1057.83 ( 243–1736)	785.66(377–1357)	577.28(142–1310)	-	0.015
CD4+ cell count - cell/μl	666.77(79–1320)	520.5(207–1000)	402.57(79–883)	-	0.081
CD8+ cell count - cell/μl	391.05(107-892)	265.16(75–548)	174.71(58–427)	-	0.011
CD4+ cell percentage - %	-	45.87 ( 42.32–50.93 )	39.85 ( 10.83–59.3 )	31.23	0.546
CD8+ cell percentage	-	24.77 ( 22.08–28.67 )	26.18 ( 14.67–46.04 )	15.54	0.436
CD3+ cell percentage - %	-	72.84 ( 70.68–74.79 )	68.87 ( 58.64–86.66 )	47.77	0.195
NK cell percentage - %	-	5.18 ( 3.54–6.47 )	11.71 ( 2.69–27.59 )	7.64	0.346
Number of lung lobes					
involved - no./total					
no.(%)					
5	12/45 ( 26.7 )	29/48 ( 60.4 )	16/25 ( 64.0 )	5/10 ( 50.0 )	0.003
4	2/45 ( 4.5 )	7/48 ( 14.6 )	2/25 ( 8.0 )	0/10 ( 0 )	0.336
3	3/45 ( 6.7 )	4/48 ( 8.3 )	4/25 ( 16.0 )	4/10 ( 4.0 )	0.032
2	11/45 ( 24.4 )	4/48 ( 8.3 )	2/25 ( 8.0 )	0/10 ( 0 )	0.073
1	11/45 ( 24.4 )	2/48 ( 4.2 )	0/25 ( 0 )	1/10 ( 10.0 )	0.003

0	6/45 ( 13.3 )	2/48 ( 4.2 )	1/25 ( 4.0 )	0/10 ( 0 )	0.343
Treatment - no./total					
no.(%)					
Antiviral	21/52 ( 40.4 )	39/70 ( 55.7 )	25/35 ( 71.4 )	6/12 ( 50.0 )	0.047
Antibiotics	48/52 ( 92.3 )	66/70 ( 94.3 )	32/35 ( 91.4 )	8/12 ( 66.7 )	0.001
Corticosteroids	6/52 ( 11.5 )	19/70 ( 27.1 )	18/35 ( 51.4 )	0/12 ( 0 )	0.001
Prognosis - no./total					0.24
no.(%)					
Death	0/52 ( 0 )	2/70 ( 2.9 )	1/35 ( 2.9 )	1/12 ( 8.3 )	
improve	52/52 ( 100.0 )	68/70 ( 97.1 )	34/35 ( 97.1 )	11/12 ( 91.7 )	

IQR=interquartile range, COPD=chronic obstructive pulmonary disease, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatine kinase-MB, PT=prothrombin time, Ig=immunoglobulin, IL=interleukin, C3=complement 3, C4=complement 4, CD=cluster of differentiation, NK= natural killer

Comparison between groups (P<0.05):AB= A compared with B, AC= A compared with C, AD=A compared with D, BC=B compared with C, BD=B compared with D, CD=C compared with D.

Table 3. Features of study subjects based on presence of comorbidities

	Have comorbidities	Have no comorbidities	
	( N=52 )	( N=117 )	p value
Disease severity- no./total no.(%)			0.004
Mild	1/52 ( 1.9 )	11/117 ( 9.4 )	0.108
Moderate	40/52 ( 76.9 )	97/117 ( 82.9 )	0.360
Severe	5/52 ( 9.6 )	8/117 ( 6.8 )	0.542
Critical	6/52 ( 11.6 )	1/117 ( 0.9 )	0.004
Sex - no./total no.(%)			0.368
Male	27/52 ( 51.9 )	52/117 ( 44.4 )	-
Female	25/52 ( 48.1 )	65/117 ( 55.6 )	-
Age inyrs- median (IQR)	59.88 ( 25–86 )	48.69 ( 18–92 )	0.001
Days from onset of illness to confirmation of diagnosis - median (IQR) Symptoms - no./total no.(%)	11.18 ( 0–40 )	11.86 ( 0–45 )	0.691
Fever	43/52 ( 82.7 )	87/117 ( 74.4 )	0.235
Dry cough	39/52 ( 75.0 )	76/117 ( 68.0 )	0.196
Sputum production	17/52 ( 33.3 )	29/117 ( 24.8 )	0.253
Shortness of breath	19/52 ( 36.5 )	19/117 ( 16.2 )	0.004
Digestive symptoms	6/52 ( 11.5 )	9/117 ( 7.7 )	0.604
Myalgia	9/52 ( 17.6 )	20/117 ( 17.1 )	0.931
Laboratory indings-median (IQR)			
SpO <sub>2</sub> - %	94.4 ( 70–99 )	96.3 ( 72–100 )	0.121

Total protein - g/L	65.66 ( 39–84 )	70.06 ( 36.7–98 )	0.004
Albumin - g/L	36.34 ( 18–53 )	39.9 ( 20–53.8 )	0.002
Globulin - g/L	29.28 ( 18–47.2 )	30.12 ( 9.8–54.5 )	0.458
Total bilirubin - μmol/L	16.65 ( 4.3–62 )	10.91 ( 2.7–49.2 )	0.006
ALT-U/L	33.96 ( 2–120 )	49.32 ( 10–574.7 )	0.046
AST-U/L	38.94 ( 5–207 )	44.54 ( 9–584 )	0.476
GGT-U/L	71.33 ( 10–601 )	81.99 ( 7–906 )	0.706
Creatinine - µmol/L	81.69 ( 43–359 )	69.45 ( 34.5–241 )	0.177
White blood cell count $- \times 10^9/L$	7.74 ( 1.01–65 )	6.77 ( 1.92–60.9 )	0.404
Neutrophil count - $\times 10^9/L$	5.44 ( 0.52–20.71 )	4.96 ( 0.8–55.6 )	0.646
$\begin{array}{c} Lymphocyte\ count\ -\\ \times 10^9/L \end{array}$	1.07 ( 0.18–2.66 )	1.31 ( 0.26–4.11 )	0.032
Hemoglobin - g/L	127.95 ( 84–191 )	131.57 ( 100–230 )	0.331
Platelet count - $\times 10^9/L$	213.34 ( 85–392 )	226.73 ( 55–564 )	0.292
C-reactive protein - mg/L	49.72 ( 0.3–254.35 )	27.22 ( 0.04–285 )	0.026
PCT -μg/mL	0.53 ( 0.02–6.02 )	0.27 ( 0.02–1.74 )	0.091
ESR - mm/h	44.67 ( 20–97.3 )	37.62 ( 9–119 )	0.175
LDH - U/L	327.21 ( 123–808 )	235.51 ( 120–681 )	0.002
Creatinekinase - U/L	106.45 ( 12–600 )	107.91 ( 28–1381 )	0.961
CK-MB - U/L	16.37 ( 5–73 )	12.68 ( 1–45.7 )	0.181
D-dimer -µg/ml	3.33 ( 0–80 )	0.71 ( 0.01–8.00 )	0.175
PT-s	18.18 ( 10.9–100 )	13.22 ( 9.7–17.4 )	0.101
Immunological			
findings- median (IQR)			

IgG- g/L	2.32 ( 1.37–3.54 )	2.46 ( 1.32–5.09 )	0.625
IgA- g/L	1.43 ( 0.46–2.98 )	1.37 ( 0.38–3.15 )	0.785
IgM- g/L	120.19 ( 0.8–1100 )	99.05 ( 1.3–1008 )	0.770
IgE- g/L	11.5 ( 7.24–16.88 )	13.03 ( 7.42–20.81 )	0.229
C3- g/L	0.91 ( 0.6–1.2 )	0.93 ( 0.6–1.4 )	0.719
C4- g/L	0.18 ( 0.1–0.3 )	0.2 ( 0.1–0.4 )	0.433
IL-6- pg/mL	17.67 ( 1.5–124.8 )	23.42 ( 0-252.7 )	0.773
CD3+ cell count - cell/µl	65.6 ( 58.64–75.45 )	69.59 ( 47.77–86.66 )	0.487
CD4+ cell count - cell/µl	12.48 ( 2.69–27.59 )	8.9 ( 3.54–18.76 )	0.379
CD8+ cell counts - cell/µl	14.99 ( 1.8–37.85 )	17.61 ( 3.3–37.33 )	0.673
CD4+ cell percentage - %	36.61 ( 10.83–59.3 )	42.41 ( 31.23–55 )	0.376
CD8+ cell percentage - %	26.85 ( 14.67–46.04 )	28.8 ( 15.54–73.05 )	0.816
Days before negative nucleic acid test-median (IQR)	8.18 ( 2–30 )	6.16 ( 1–18 )	0.092
Treatment - no./total			
no. (%) Antibiotics	33/52 ( 63.50 )	58/117 ( 49.6 )	0.095
Antiviral	49/52 ( 94.2 )	105/117 ( 89.7 )	0.558
Corticosteroids	16/52 ( 30.8 )	32/117 ( 27.4 )	0.649
Outcome - no./total no.			0.008
Death	4/52 ( 7.7 )	0/117 ( 0 )	
Improvement	48/52 ( 92.3 )	117/117 ( 100 )	

IQR=interquartile range, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatine kinase-MB, ESR=erythrocyte sedimentation rate, PT=prothrombin time, Ig=immunoglobulin

402 Table 4:Relationship between age and disease severity ( N=169 )

401

404

405

406

Variable	В	$Wald\chi^2$	P	95%CI
Q1	-4.604	32.983	0.000	( -6.175~-3.033 )
Q2	0.512	0.586	0.444	( -0.799~1.823 )
Q3	1.770	6.063	0.014	( 0.361~3.180 )
Age group (control: group 5)				
1	-2.675	8.098	0.004	( -4.518~-0.883 )
2	-2.382	8.146	0.004	( -4.017~-0.746 )
3	-1.768	5.022	0.025	( -3.314~-0.222 )
4	-0.628	0.691	0.406	( -2.110~0.853 )

403 Q1=Mild disease, Q2=Moderate disease, Q3=Severe disease, Q4=Critical disease

Age group (years, 15-year intervals): 1=18-32, 2=33-47, 3=48-62, 4=63-77, 5=78-92; B=regression

coefficient; OR=odds ratio; 95% CI=95% confidence interval

407 Table 5:Univariable and multivariable analyses of risk factors for disease severity ( N=169 )

Variable	Univariable analysis	N	Multivariable analysis			
	P	P	OR	95%CI		
SpO <sub>2</sub> (%)	0.000	0.000	0.693	(0.572-0.839)		
Age(Year)	0.003	0.482	-	-		
Lymphocytes(×10 <sup>9</sup> /L)	0.000	0.047	0.176	(0.032-0.976)		
CRP rise(No)	0.003	0.212	-	-		
LDH rise(No)	0.002	0.974	-	-		
Administration of corticosteroids	0.000	0.505	-	-		
Days from onset of illness to confirmation of	0.049	0.070	-	-		

diagnosis time				
Underlying disease(No)	0.043	0.185	-	
Albumin (g/L)	0.002	-	-	-
D-dimer (µg/ml)	0.019	0.307	1.056	(0.951-1.171)
Dyspnea(No)	0.000	0.270	-	-
Cough(No)	0.032	-	-	-

LDH=lactate dehydrogenase; CRP=C-reactive protein; OR=odds ratio; 95%CI=95% confidence interval

Table6: Chest CT findings of study subjects on different days\*

	On admission	Group1(≤7	Group2(8-14	Group3(15-21days)	Group4(22-28days)	Group5(29-45	Group6(46-60days)	p value
		days)	days)			days)		
Number of patients	116	59	92	109	60	52	18	
Days from onset of	10.73±7.97	4.610±2.14	11.09±1.93			34.58±5.18		
illness to chest CT-median (IQR)	( 0-34 )	( 0–7 )	( 8–14 )	17.72±2.01 ( 15–21 )	24.98±1.92 ( 22–28 )	( 29–45 )	51.72±3.64 ( 45–57 )	
Bilateral lung involvement - no./total no.(%)	84/116 ( 72.4 )	39/59 ( 66.1 )	68/92 ( 73.9 )	87/109 ( 79.8 )	51/60 ( 85 )	39/52 ( 75 )	12/18 ( 66.7 )	0.158
Distribution of lesions in lung-no./total no.(%)								
Peripheral		41/59	72/92	92/109		47/52	17/18	
-	88/116( 75.86 )	( 69.49 )	( 78.26 )	( 84.40 )	55/60 ( 91.67 )	( 90.38 )	( 94.44 )	0.006
Along the bronchi		10/59	32/92	33/109		11/52	2/18	
	30/116( 25.86 )	( 16.95 )	( 34.78 )	( 30.28 )	12/60 ( 20.00 )	(21.15)	( 11.11 )	0.049
Random	3/116 ( 2.59 )	4/59 ( 6.78 )	2/92 ( 2.17 )	1/109 ( 0.92 )	0/60 ( 0 )	0/52 ( 0 )	0/18 ( 0 )	0.101
Diffuse	11/116 ( 9.48 )	4/59 ( 6.78 )	6/92 ( 6.52 )	9/109 ( 8.26 )	2/60 ( 3.33 )	1/52 ( 1.92 )	1/18 ( 5.56 )	0.638
CT								

5	56/116( 48.28 )	( 33.90 )	(46.74)	( 53.21 )	33/60 ( 55.00 )	(53.85)	(66.67)	0.079
_	FC(11.6) 40.00 \	20/59	43/92	58/109	22/(0./.55.00.)	28/52	12/18	0.070
no.(%)								
involved-no./total								
lobes								
Number of lung								
	40/116( 34.48 )	( 20.34 )	(30.43)	( 43.12 )	25/60 (41.67)	(61.54)	( 33.33 )	0.001
Vascular thickening		12/59	28/92	47/109		32/52	6/18	
Pleural effusion	2/116 ( 1.72 )	1/59 ( 1.69 )	0/92 ( 0 )	2/109 ( 1.83 )	1/60 ( 1.67 )	1/52 ( 1.92 )	0/18 ( 0 )	0.753
Pleural thickening	6/116 ( 5.17 )	0/59 ( 0 )	3/92 ( 3.26 )	9/109 ( 8.26 )	7/60 ( 11.67 )	9/52 ( 17.31 )	3/18 ( 16.67 )	0.001
Reticular change	15/116( 12.93 )	4/59(6.78)	5/92 ( 5.43 )	18/109 ( 16.51 )	13/60 ( 21.67 )	13/52 ( 25.00 )	7/18 ( 38.89 )	0.001 ¥
Linear opacity	64/116(55.2)	20/59(33.9)	53/92(57.6)	91/109(83.5)	56/60(93.3)	51/52(98.1)	18/18(100)	0.001
opacity with consolidation	39/116(33.6)	16/59(27.1)	31/92(33.7)	34/109(31.2)	12/60(20.0)	16/55(29.1)	6/18(33.3)	0.337
<b>Ground-glass</b>								
Consolidation	77/116(66.4)	30/59(50.9)	72/92(78.3)	80/109(73.4)	37/60(61.7)	33/55(63.6)	14/18(77.8)	0.004@
Ground-glass opacity	64/116(55.2)	48/59(81.4)	48/92(52.2)	41/109(37.6)	17/60(28.3)	19/52(36.5)	8/18(44.4)	0.001#
no.(%)								
findings-no./total								

		6/59	7/92	14/109		7/52		
4	10/116( 8.662 )	( 10.17 )	( 7.61 )	( 12.84 )	6/60 ( 10.00 )	(13.46)	0/18 ( 0 )	0.530
		10/59	11/92	9/109	4/60	11/52	6/18	
3	16/116( 13.79 )	( 16.95 )	( 11.96 )	(8.26)	( 6.67 )	(21.15)	( 33.33 )	0.011
		12/59	20/92	18/109		4/52		
2	17/116( 14.66 )	( 20.34 )	(21.74)	( 16.51 )	12/60 ( 20.00 )	(7.69)	0/18 ( 0 )	0.100
		11/59	11/92	10/109	5/60	2/52		
1	17/116( 14.66 )	( 18.64 )	( 11.96 )	( 9.17 )	( 8.33 )	(3.85)	0/18 ( 0 )	0.083

<sup>\*</sup> Days from onset of illness to chest CT examination

CT=computed tomography, IQR=interquartile range

<sup>#:</sup> Group1 compared to other groups; Group2 compared to Group3 and Group4; p<0.05

<sup>@:</sup> Group1 compared toGroup2, Group3, and Group4; Group2 compared toGroup5; p<0.05

 $<sup>\</sup>mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath{\mbox{\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremath}\ensuremat$ 

Table 7:Univariable and multivariable analysis of factors associated with the time it takes for nucleic acid test to turn negative (N=79)

Variable	Univariable analysis	Multivariable analysis		
	P	P	В	95%CI
Sex(Male)	0.079	-	-	-
Age(Year)	0.278	-	-	-
Lymphocytes(×10 <sup>9</sup> /L)	0.005	0.014	-2.974	(-5.327~-0.620)
CRP(mg/L)	0.021	0.954	0.001	(-0.022~0.024)
LDH(U/L)	0.005	0.730	0.003	(-0.012~0.017)
Corticosteroids	0.005	0.137	-1.710	(-3.978~0.557)
Antibiotics	0.024	0.154	-1.563	(-3.723~0.598)

LDH=lactate dehydrogenase; CRP=C-reactive protein; B=Regression coefficients; 95%CI=95% confidence interval

Table 8:Univariable and multivariable analysis of factors associated with the time it takes for symptoms to improve ( N=53 )

Variable	Univariable analysis	M	Multivariable analysis			
	P	P	В	95%CI		
Sex(Male)	0.724	-	-	-		
Age(Year)	0.052	0.095	0.146	(-0.025~0.319)		
Lymphocytes(×10 <sup>9</sup> /L)	0.029	0.440	1.713	(-2.708~6.134)		
CRP(mg/L)	0.993	-	-	-		
$LDH(\mu/L)$	0.792	-	-	-		
Administration of corticosteroid	0.323	-	-	-		
Timefrom onset of						
illness to confirmation of	0.000	0.001	0.527	(0.219~0.835)		
diagnosis (days)						

LDH=lactate dehydrogenase; CRP=C-reactive protein; B=Regression coefficients; 95%CI=95% confidence interval

Table 9:Univariable and multivariable analysis of factors associated with chest CT improvement (N=62)

Variable	Univariable analysis	M	Multivariable analysis			
	P	P	HR	95%CI		
Sex(Male)	0.023	0.109	0.608	(0.331-1.117)		
Age(Year)	0.195	-	-	-		
Lymphocytes(×10 <sup>9</sup> /L)	0.088	0.278	1.374	(0.774-2.440)		
CRP(mg/L)	0.561	-	-	-		
LDH(U/L)	0.899	-	-	-		
Administration of corticosteroid	0.540	-	-	-		
Time from onset of						
illness to confirmation of	0.075	0.013	1.019	(1.019–1.168)		
diagnosis (days)						
Disease severity	0.045	0.061	-	-		
Moderate(compared to mild mild)	-	0.008	0.261	(0.097–0.704)		
Severe(compared to mild mild)	-	0.057	0.192	(0.035–1.049)		
Critical(compared to mild mild)	-	0.971	0	0		
Time of onset to nucleic acid positive time(days)	0.059	0.853	1.009	(0.918–1.110)		

CT=computed tomography, LDH=lactate dehydrogenase, CRP=C-reactive protein, HR=hazard ratio, 95% CI=95% confidence interval

## **Figurelegends**

**Figure 1**: Computed tomography findings in the lungs on different days in the course of the disease in a patient with severe disease.(a)4 days from onset of illness.(b)8 days from illness onset ( patient's clinical symptoms began to improve ) .(c)13 days from onset of illness. (d)18 days from onset of illness. (e)23 days from onset of illness onset.

Figure 2: Computed tomography findings in the lungs on different days in the course


of the disease in a patient with moderate disease. (a)5 days from onset of illness. (b)10 days from onset of illness (patient's clinical symptoms began to improve). (c)15 days from onset of illness. (d)21 days from onset of illness.


Figure 3: Correlations between: The days of nucleic acid test turned negative and


lymphocytes;


Figure 4: Correlations between: Time from onset of symptoms to confirmation of

diagnosis and Time it took for symptoms to improve.









Time from onset of symptoms to confirmation of diagnosis(Day)